TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7109892

Group type: EXPERIMENTAL
Intervention: RUN‐CWT
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: CWT
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study: 31836104

Group type: EXPERIMENTAL
Intervention: Win‐flash Perceptual Learning training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 14
Study: 27881297

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26484516

Group type: EXPERIMENTAL
Intervention: Nordic Walking group (NWg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Cg)
Number of subjects: 20
Study: 23868279

Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified bilateral arm training with rhythmic auditory cueing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dose‐matched conventional treatment
Number of subjects: 60
Study: 21633398

Group type: EXPERIMENTAL
Intervention: Eucaloric energy intake
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 30% overfeeding
Number of subjects: 42
Study: 19521296

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (non-homozygous 4G/4G patients)
Number of subjects: 260
Study: 17568029

Group type: EXPERIMENTAL
Intervention: Fluconazole 6 mg/kg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Fluconazole 3 mg/kg
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 16179042

Group type: EXPERIMENTAL
Intervention: Acupressure at extra 1 point
Number of subjects: 76

Group type: COMPARATOR
Intervention: Acupressure at an inappropriate site (Control)
Number of subjects: 76
Study: 12113651

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream applied twice daily for 3 weeks in adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream applied twice daily for 6 weeks in infants and children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream (intermittent long-term use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1.0% cream for 1 year
Number of subjects: 0
Study: 10569156

Group type: EXPERIMENTAL
Intervention: Topical intrastromal steroid (prednisolone sodium phosphate 1% solution) applied on the undersurface of the cap immediately after it was reflected.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard LASIK medication protocol (no steroid application).
Number of subjects: 210
Study: 7546467

Group type: EXPERIMENTAL
Intervention: VariGlass VLC glass ionomer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Concise resin sealants
Number of subjects: 48
Study: 2125793

Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 377458

Group type: EXPERIMENTAL
Intervention: Acute excision (A) - operation within 24 hours post burn
Number of subjects: 2460

Group type: COMPARATOR
Intervention: Exposure method (E) - exposure followed by excision and transplantation no later than day 14 post burn
Number of subjects: 2460
Study: 31975316

Group type: EXPERIMENTAL
Intervention: Red clover preparation (Promensil® Forte) 80 mg/day for 24 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (one oral tablet/day without active ingredient)
Number of subjects: 81
Study: 31473079

Group type: EXPERIMENTAL
Intervention: KnowIt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OnTrack
Number of subjects: 0
Study: 28724914

Group type: EXPERIMENTAL
Intervention: Computer‐based cognitive training on six adaptive tests of executive function
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Cognitive and physical exercise training
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Cognitive training combined with non‐invasive brain stimulation and physical exercise training
Number of subjects: 318

Group type: COMPARATOR
Intervention: Active control training in adaptive visual search and change detection tasks
Number of subjects: 318

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 318
Study: 25837216

Group type: EXPERIMENTAL
Intervention: Ginger 1000mg/d for 10 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24028998

Group type: EXPERIMENTAL
Intervention: Increased T-wave alternans (TWA) and QT variability (QTV) combined (specifically IAA90 and QTVN)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: TWA
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: QTV
Number of subjects: 175
Study: 22071707

Group type: EXPERIMENTAL
Intervention: Uncalibrated energy consumption (20% increment)
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated energy consumption (20% increment)
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Uncalibrated energy consumption (20% increment) after adjustment for BMI
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Uncalibrated protein intake (g/d) (20% increment)
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated protein intake (g/d) (20% increment)
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Uncalibrated protein intake (g/d) (20% increment) after adjustment for BMI
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Uncalibrated protein density (% of energy from protein) (20% increment)
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Biomarker-calibrated protein density (% of energy from protein) (20% increment)
Number of subjects: 74155

Group type: EXPERIMENTAL
Intervention: Uncalibrated protein density (% of energy from protein) (20% increment) after adjustment for BMI
Number of subjects: 74155
Study: 19750191

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (treated only with drugs)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: GOLD stages 2, 3, and 4
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: GOLD stage 1
Number of subjects: 284
Study: 16894423

Group type: EXPERIMENTAL
Intervention: DTPA(+) method
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: (99m)Tc-DTPA plasma disappearance curve
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DTPA(-) method
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Plasma clearance of creatinine by 24-hour urine collection
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Plasma clearance of creatinine by Cockcroft-Gault formula
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Radionuclidic methods (DTPA(+), DTPA(-), (99m)Tc-DTPA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Creatinine clearance with 24-hour urine collection
Number of subjects: 82
Study: 12520563

Group type: EXPERIMENTAL
Intervention: Rank-based procedures for testing non-inferiority and equivalence hypotheses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric procedures
Number of subjects: 0
Study: 11093989

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (D10)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (D5)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg (D2.5)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.25 mg (D1.25)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 225
Study: 8936243

Group type: EXPERIMENTAL
Intervention: Health promotion needs identification
Number of subjects: 148
Study: 1357295

Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (0.1 microgram/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tracheal adrenaline (0.5 microgram/kg)
Number of subjects: 12
Study: 3908500

Group type: EXPERIMENTAL
Intervention: 30 mg of ciramadol
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: 60 mg of ciramadol
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: 60 mg of codeine
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 31038010

Group type: EXPERIMENTAL
Intervention: Highly-objectified women in alcohol advertisements
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Low-objectified women in alcohol advertisements
Number of subjects: 1208
Study: 29314160

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Systemic family therapy (SyFT)
Number of subjects: 158
Study: 26996093

Group type: EXPERIMENTAL
Intervention: Inpatient exercise-based rehabilitation program (n=32)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Respiratory physiotherapy regimen (n=17)
Number of subjects: 49
Study: 23979965

Group type: EXPERIMENTAL
Intervention: Besifovir 90 mg daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Besifovir 150 mg daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Entecavir 0.5 mg daily
Number of subjects: 114
Study: 22845485

Group type: EXPERIMENTAL
Intervention: T'ai chi intervention (n=16)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual-care group (n=12)
Number of subjects: 28
Study: 20385794

Group type: EXPERIMENTAL
Intervention: rFVIIa (80 microg/kg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 18682881

Group type: EXPERIMENTAL
Intervention: (60)Cu-ATSM-PET imaging
Number of subjects: 17
Study: 15699752

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12654753

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg once daily for 3 days
Number of subjects: 48
Study: 10668522

Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: sulfasalazine
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: methotrexate
Number of subjects: 580

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 580
Study: 8905480

Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1715125

Group type: EXPERIMENTAL
Intervention: Imazodan 2 mg administered twice daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Imazodan 5 mg administered twice daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Imazodan 10 mg administered twice daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Imazodan
Number of subjects: 147
Study: 6869493

Group type: EXPERIMENTAL
Intervention: Cognitive skill remediation program (30 minutes per day, 3 days per week, for 3 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (conventional therapies continued)
Number of subjects: 33
Study: 30417848

Group type: EXPERIMENTAL
Intervention: Filtek Bulk‐Fill Restorative (FBF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Filtek Z250 (conventional composite)
Number of subjects: 80
Study: 26821623

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg intravenous CsA
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control
Number of subjects: 410
Study: 24556041

Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin 85 mg/m², leucovorin 200 mg/m², bolus fluorouracil 400 mg/m², infusional fluorouracil 1600 mg/m²)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Fluorouracil and cisplatin (fluorouracil 1000 mg/m² per day for 4 days and cisplatin 75 mg/m² on day 1)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 267

Group type: COMPARATOR
Intervention: Fluorouracil and cisplatin
Number of subjects: 267
Study: 22445676

Group type: EXPERIMENTAL
Intervention: Metronome guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No metronome guidance (Control)
Number of subjects: 0
Study: 20385926

Group type: EXPERIMENTAL
Intervention: Early treatment for high-risk prethreshold ROP
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early treatment for Type 1 eyes
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management for Type 1 eyes
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early treatment for Type 2 eyes
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management for Type 2 eyes
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management for high-risk prethreshold ROP
Number of subjects: 401
Study: 18602754

Group type: EXPERIMENTAL
Intervention: Bilateral coordinative exercise (CE)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Normal sport lesson (NSL)
Number of subjects: 115
Study: 16157829

Group type: EXPERIMENTAL
Intervention: PSA levels 0 to 0.49 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 0.50 to 0.99 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 1.00 to 1.49 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 1.50 to 1.99 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 2.00 to 2.49 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 2.50 to 2.99 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 3.00 to 3.99 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 4.00 to 6.99 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 7.00 to 9.99 ng/mL
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: PSA levels 10.00 ng/mL or higher
Number of subjects: 5855

Group type: EXPERIMENTAL
Intervention: Initial PSA level less than 1 ng/mL
Number of subjects: 5855
Study: 12392345

Group type: EXPERIMENTAL
Intervention: Functional condition (reach to press a light switch to turn on a red light)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Semi-functional condition (reach to press the light switch; no light)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonfunctional condition (reach to a marker)
Number of subjects: 12
Study: 9934423

Group type: EXPERIMENTAL
Intervention: Braced group (rehabilitative braces for 2 weeks, functional braces for 10 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonbraced group (no braces)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Braced group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonbraced group
Number of subjects: 60
Study: 7752005

Group type: EXPERIMENTAL
Intervention: Pulse doses of dexamethasone, 0.5 mg/kg per day, divided twice daily for 3 days at 10-day intervals
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 78
Study: 2281237

Group type: EXPERIMENTAL
Intervention: Logistic regression with paired Bernouilli outcomes
Number of subjects: 0
Study: 7446190

Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bilateral ECT
Number of subjects: 29
Study: 31127593

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 28356319

Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Postmeal faster aspart
Number of subjects: 1143

Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1143
Study: 25918728

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 32
Study: 24011655

Group type: EXPERIMENTAL
Intervention: Seated thoracic manipulation (high velocity, low amplitude)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham group (same procedure without high-velocity thrust)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Seated thoracic manipulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 42
Study: 21865563

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Folic acid + iron supplementation
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Folic acid + iron + zinc supplementation
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 1132
Study: 19107946

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fractionated radiotherapy (SFX)
Number of subjects: 0
Study: 17683563

Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open sigmoid resection
Number of subjects: 0
Study: 15523952

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK using the WASCA workstation and the Asclepion Meditec flying spot MEL 70 excimer laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional PRK using the same laser
Number of subjects: 60
Study: 11176156

Group type: EXPERIMENTAL
Intervention: Inverse Ratio Ventilation (IRV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal Ratio Ventilation
Number of subjects: 22
Study: 10944051

Group type: EXPERIMENTAL
Intervention: Early surgical intervention with ventilation tubes
Number of subjects: 182

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 182
Study: 9072052

Group type: EXPERIMENTAL
Intervention: HELISAL
Number of subjects: 61
Study: 1578091

Group type: EXPERIMENTAL
Intervention: Vitamins B1, B2, and B6 (10 mg each)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3881692

Group type: EXPERIMENTAL
Intervention: mesulergine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31125491

Group type: EXPERIMENTAL
Intervention: Olmutinib 100-300 mg
Number of subjects: 56
Study: 29161901

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid (ALA) PDT
Number of subjects: 58

Group type: COMPARATOR
Intervention: Photofrin PDT
Number of subjects: 58
Study: 26915064

Group type: EXPERIMENTAL
Intervention: Noise group (80 dB verbal recording)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (silence)
Number of subjects: 70
Study: 25189917

Group type: EXPERIMENTAL
Intervention: Complementary treatment with sodium selenite, proteolytic plant enzymes and Lc-lectin
Number of subjects: 93
Study: 22519543

Group type: EXPERIMENTAL
Intervention: Subcutaneous nadroparin calcium (200 I.U./kg/day) for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral pentoxifylline (control)
Number of subjects: 24
Study: 20188364

Group type: EXPERIMENTAL
Intervention: Purified urinary FSH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 0
Study: 17919374

Group type: EXPERIMENTAL
Intervention: Hypocaloric and hypo-nitrogen parenteral nutrition (PN) with 18 (range 16-20) kcal x kg(‐1) x d(‐1) and nitrogen 0.10 (0.09-0.11) g x kg(‐1) x d(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hypocaloric and hypo-nitrogen parenteral nutrition (PN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group receiving PN with 30 (28-32) kcal x kg(‐1) x d(‐1) and nitrogen 0.20 (0.19-0.21) g x kg(‐1) x d(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 16030079

Group type: EXPERIMENTAL
Intervention: 12-week individualized home-based moderate-intensity exercise programme
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 79
Study: 12140028

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Untreated fellow eye
Number of subjects: 7
Study: 10221413

Group type: EXPERIMENTAL
Intervention: Meropenem (0.5 g/8 h)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (0.5 g/6 h)
Number of subjects: 161
Study: 8563365

Group type: EXPERIMENTAL
Intervention: Computer-generated reminder system for diabetes care guidelines
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonspecific report (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Encounter forms used by the system
Number of subjects: 35

Group type: COMPARATOR
Intervention: No encounter forms used
Number of subjects: 35
Study: 2353713

Group type: EXPERIMENTAL
Intervention: Representational figures (arrow, house, face)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonrepresentational figures (geometric shapes)
Number of subjects: 30
Study: 31349348

Group type: EXPERIMENTAL
Intervention: Decreased time to hemostasis
Number of subjects: 680
Study: 28385445

Group type: EXPERIMENTAL
Intervention: Digital impressions with stereophotogrammetry
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional impressions
Number of subjects: 18
Study: 26521190

Group type: EXPERIMENTAL
Intervention: 125 mg furosemide with HSS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 250 mg furosemide with HSS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 500 mg furosemide with HSS
Number of subjects: 42
Study: 23480923

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5mg/kg) and ketamine (5mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral midazolam (0.5mg/kg), acetaminophen (10mg/kg), and codeine (1mg/kg)
Number of subjects: 60
Study: 22258912

Group type: EXPERIMENTAL
Intervention: 1-hour psychoeducational group therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care (no group therapy)
Number of subjects: 91
Study: 19267777

Group type: EXPERIMENTAL
Intervention: MMF (2 g/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRL (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PRED dose reduction
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TAC drug exposure
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRL drug exposure
Number of subjects: 25